Pharmacokinetics of Drugs in Cachectic Patients: a Systematic Review

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Nov 28

PMID 24282510

Citations 35

Authors

Katja Trobec

Mojca Kerec Kos

Stephan von Haehling

Jochen Springer

Stefan D Anker

Mitja Lainscak

Affiliations

Soon will be listed here.

Abstract

Cachexia is a weight-loss process caused by an underlying chronic disease such as cancer, chronic heart failure, chronic obstructive pulmonary disease, or rheumatoid arthritis. It leads to changes in body structure and function that may influence the pharmacokinetics of drugs. Changes in gut function and decreased subcutaneous tissue may influence the absorption of orally and transdermally applied drugs. Altered body composition and plasma protein concentration may affect drug distribution. Changes in the expression and function of metabolic enzymes could influence the metabolism of drugs, and their renal excretion could be affected by possible reduction in kidney function. Because no general guidelines exist for drug dose adjustments in cachectic patients, we conducted a systematic search to identify articles that investigated the pharmacokinetics of drugs in cachectic patients.

Citing Articles

Metabolic, Inflammatory, and Molecular Impact of Cancer Cachexia on the Liver.

Goncalves D, Gomes S, Seelaender M Int J Mol Sci. 2024; 25(22).

PMID: 39596015 PMC: 11593664. DOI: 10.3390/ijms252211945.

Postoperative pain management using high-dose oral acetaminophen for enhanced recovery after colorectal cancer surgery.

Urakawa S, Shingai T, Kato J, Kidogami S, Fukata T, Nishida H Surg Today. 2024; .

PMID: 39535594 DOI: 10.1007/s00595-024-02962-3.

Factors Associated With Sacubitril/Valsartan Continuation and the Methods of Combining Heart Failure Medications in Patients With Heart Failure.

Iwasaki E, Kohyama N, Inamoto M, Nagao M, Sunaga T, Suzuki H Ann Pharmacother. 2024; 59(4):301-310.

PMID: 39229914 PMC: 11874506. DOI: 10.1177/10600280241277354.

Pharmacokinetics of Antibacterial Agents in the Elderly: The Body of Evidence.

Butranova O, Ushkalova E, Zyryanov S, Chenkurov M, Baybulatova E Biomedicines. 2023; 11(6).

PMID: 37371728 PMC: 10296334. DOI: 10.3390/biomedicines11061633.

Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation.

Kipourou M, Begou O, Manika K, Ismailos G, Kontou P, Pitsiou G Antibiotics (Basel). 2023; 12(2).

PMID: 36830217 PMC: 9952492. DOI: 10.3390/antibiotics12020307.

References

Jacques K, Erstad B . Availability of information for dosing injectable medications in underweight or obese patients. Am J Health Syst Pharm. 2010; 67(22):1948-50. DOI: 10.2146/ajhp100226. View

Barry R . Malignancy, weight loss, and the small intestinal mucosa. Gut. 1974; 15(7):562-70. PMC: 1412980. DOI: 10.1136/gut.15.7.562. View

Naito T, Tashiro M, Yamamoto K, Ohnishi K, Kagawa Y, Kawakami J . Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Eur J Clin Pharmacol. 2012; 68(10):1411-8. DOI: 10.1007/s00228-012-1266-x. View

Herrington J, Tran H, Riggs M . Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia. Cancer Chemother Pharmacol. 2005; 57(2):241-7. DOI: 10.1007/s00280-005-0012-9. View

Trobec K, Knez L, Brguljan P, Cufer T, Lainscak M . Estimation of renal function in lung cancer patients. Lung Cancer. 2011; 76(3):397-402. DOI: 10.1016/j.lungcan.2011.11.016. View

McLeay S, Morrish G, Kirkpatrick C, Green B . The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012; 51(5):319-30. DOI: 10.2165/11598930-000000000-00000. View

Evans W, Morley J, Argiles J, Bales C, Baracos V, Guttridge D . Cachexia: a new definition. Clin Nutr. 2008; 27(6):793-9. DOI: 10.1016/j.clnu.2008.06.013. View

Chien J, Ho R . Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J Pharm Sci. 2010; 100(1):53-8. PMC: 4867146. DOI: 10.1002/jps.22253. View

Mulligan H, Beck S, Tisdale M . Lipid metabolism in cancer cachexia. Br J Cancer. 1992; 66(1):57-61. PMC: 1977893. DOI: 10.1038/bjc.1992.216. View

10.

Morgan E, Goralski K, Piquette-Miller M, Renton K, Robertson G, Chaluvadi M . Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008; 36(2):205-16. DOI: 10.1124/dmd.107.018747. View

11.

Brantley R, Williams K, Silva T, Sistrom M, Thielman N, Ward H . AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. Braz J Infect Dis. 2003; 7(1):16-22. DOI: 10.1590/s1413-86702003000100003. View

12.

Trout H, Mentre F, Panhard X, Kodjo A, Escaut L, Pernet P . Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother. 2004; 48(2):538-45. PMC: 321510. DOI: 10.1128/AAC.48.2.538-545.2004. View

13.

Agustsson T, Wikrantz P, Ryden M, Brismar T, Isaksson B . Adipose tissue volume is decreased in recently diagnosed cancer patients with cachexia. Nutrition. 2012; 28(9):851-5. DOI: 10.1016/j.nut.2011.11.026. View

14.

King D, Smith M, Chapman T, Stockdale H, Lye M . Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 1996; 25(2):144-9. DOI: 10.1093/ageing/25.2.144. View

15.

von Haehling S, Anker S . Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2011; 1(1):1-5. PMC: 3060651. DOI: 10.1007/s13539-010-0002-6. View

16.

Morley J, Thomas D, Wilson M . Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83(4):735-43. DOI: 10.1093/ajcn/83.4.735. View

17.

Pichard C, Kyle U . Body composition measurements during wasting diseases. Curr Opin Clin Nutr Metab Care. 1999; 1(4):357-61. DOI: 10.1097/00075197-199807000-00008. View

18.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

19.

Pollock L, Else L, Poerksen G, Molyneux E, Moons P, Walker S . Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. J Antimicrob Chemother. 2009; 64(6):1251-9. PMC: 2775666. DOI: 10.1093/jac/dkp358. View

20.

Rauchhaus M, Coats A, Anker S . The endotoxin-lipoprotein hypothesis. Lancet. 2000; 356(9233):930-3. DOI: 10.1016/S0140-6736(00)02690-8. View